Table 2. In vivo targeting of PI5P4Ks.

Summary of the in vivo evidence of targeting PI5P4Ks in mouse models. The top half of the table comprises the phenotypes of the genetic models of kinase deletion, including germline deletions and the GEM model of sarcoma. The bottom half includes the outcomes of the multiple tumor implantation models in which PI5P4Ks were manipulated.

Genetic Mouse Models	Implicated Isoform	Phenotype
Pip4k2a −/−	PI5P4Kα	Normal health and life span [15]
Pip4k2b −/−	PI5P4Kβ	Normal life span; retarded growth; Insulin sensitivity [16]
Pip4k2c −/−	PI5P4Kγ	Hyperinflammation; increased helper T cells and reduced regulatory T cells [17]
Pip4k2a−/− Pip4k2b−/−	PI5P4Kα, PI5P4Kβ	Perinatal lethal [15]
Pip4k2b−/− Trp53−/−	PI5P4Kβ	Embryonic lethal [15]
Pip4k2a−/− Pip4k2b+/− Trp53−/−	PI5P4Kα, PI5P4Kβ	Increased tumor free survival compared to Trp53−/− [15]
KrasLSL-G12D/+ Trp53flx/flx Pip4k2aflx/flx Pip4k2b−/−	PI5P4Kα, PI5P4Kβ	Restricted tumor formation and increased survival compared to KrasLSL-Gi2D/+ Trp53flx/flx [37]
Tumor Implantation Models	Implicated Isoform	Phenotype
Xenograft
BT474 Breast cancer p53 mutant cell line	PI5P4Kα, PI5P4Kβ	Impaired tumor growth with kinase knockdown [15]
THP1 AML cell line	PI5P4Kα	No evidence of leukemic engraftment with kinase knockdown [47]
SV40 transformed MEF	PI5P4Kβ	Decreased tumor growth with GTP insensitive Pip4k2b [61]
LN428 GBM cell line	PI5P4Kα	Increased tumor growth with kinase knockdown [53]
Orthotopic
GBM cell line	PI5P4Kα	Decreased tumor growth with kinase overexpression [53]
KPS-142 Sarcoma cell line	PI5P4Kα, PI5P4Kβ	Decreased tumor growth with kinase knockdown [37]